Biotech company XenoPort Inc. (Nasdaq: XNPT) reported disappointing results for its midstage trial of its reflux disease drug treatment. The stock price plummeted $9.02 to $19.90.
Disappointing Trial Results For XenoPort
December 02, 2008 at 13:25 PM EST
